Pharmalot... Pharmalittle... Good Morning

Top of the morning to you. A gorgeous day is unfolding on the Pharmalot corporate campus, where a bright sun is shining and the air is crisp, but comfortable. To celebrate, we are downing yet another cup of stimulation - we are back to Southern Pecan - and looking forward to a busy round of phone calls, meetings and deadlines. You have your own to-do list, of course, so to help you get started, here are a few items of interest. Have a good one and stay in touch...

Avastin Fails To Help Older Lung Cancer Patients In Study (Bloomberg News)

Dendreon CEO: 'This Will Be My Last Stop' (Xconomy)

J&J Raises Forecast, But Replenishing Store Shelves Lags (Bloomberg News)

Forest Labs Profit Tumbles On Generic Lexapro (Reuters)

FDA Wants More Info On Halozyme/Baxter Drug (Pharma Times)

Aveo Pharma Leaves The Start-Up Phase (Boston Globe)

NHS Drug Spending In England Falls (Pharma Times)

China Halts Sale Of Some Drugs (Wall Street Journal)

India Eyes Penalties For Aggressive Drug Marketing (Economic Times)

Fish Oil Flops In Treating Multiple Sclerosis (MedPage Today)

Novo Nordisk Warns FDA Of Biosimilar Concerns (InPharma Technologist)

Off-Label Drug Prescribing Is Common: Study (HealthDay)

EDITOR'S NOTE: Please check this post for updates throughout the day

3 Comments

It's time to stop weeping for the Innovator who builds a successful clinical product enjoying the profitablility for many years and then suddenly (10 years later) comes to realize that their exclusivity is about to expire. They knew this would happen at least 10 years earlier but did nothing. At the very end they begin to switch from their main function of improving clinical outcomes to extending exclusivity through distracting legal maneuvers. If the generic business is good for generic companies why isn't it good for innovator who has all of the product and market knowledge?
Apr 17, 2012 - 3:38pm
If the innovative companies quit researching and developing new products, what will become of the generic companies?
Apr 17, 2012 - 7:36pm
Retired, you nailed the problem. You talked about the number 10 years. Patents are for 20 years but we need half of that to get to market. Give us another 10 years of patent life and you won't hear so much complaining out of my shop.